RheumaGen Awarded Grant from Colorado Office of Economic Development

RheumaGen was recently awarded a $250,000 Early-stage Capital and Retention grant from the Colorado Office of Economic Development and International Trade (OEDIT). The grant is aimed to support RheumaGen in commercializing its disruptive HLA gene editing technology for patients with refractory rheumatoid arthritis. OEDIT grants promote the growth and sustainability of advanced industries in Colorado.

Learn more here.